Tempus exceeds $1.1 billion in record total contract value

Tempus AI, Inc., a prominent technology company specializing in the integration of artificial intelligence to enhance precision medicine, recently disclosed an impressive Total Contract Value (TCV) surpassing $1.1 billion by the end of 2025. Throughout the year, Tempus solidified data agreements with more than 70 clientele, ranging from major pharmaceutical players like AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, and Boehringer Ingelheim to smaller biotech companies such as Incyte, Servier, Aspera Biomedicines, and Whitehawk Therapeutics. The growing trend among biopharmaceutical firms to incorporate Tempus’s distinct, multimodal dataset highlights the increasing recognition and utilization of Tempus’s services in drug discovery and development endeavors.

In conjunction with the noteworthy rise in Total Contract Value, Tempus also reported a remarkable net revenue retention rate of approximately 126% for 2025, underscoring the company’s ability to nurture and expand relationships with existing customers, even amidst a period of escalated growth and expansion.

Jim Rogers, Chief Financial Officer at Tempus, expressed his satisfaction with the company’s performance in 2025, stating, “2025 was a record year for our Data and applications business – both from a revenue and TCV perspective. Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond.”

Although financial statements for the fourth quarter and full year of 2025 have not been finalized, the current estimate of Data and applications revenue for the year ending December 31, 2025, is preliminary and subject to change as Tempus continues to review and prepare its financial results for the said period. As Tempus proceeds with its typical year-end closure and review processes for the quarter and year ending December 31, 2025, there remains a possibility of variations in the final results compared to the preliminary estimate provided. Any discrepancies identified during the preparation of Tempus’s consolidated financial statements may potentially lead to material differences in the reported results.

Looking ahead, Tempus is gearing up to unveil its complete fourth-quarter and full-year 2025 financial statements in due course, providing stakeholders with a comprehensive overview of the company’s performance, achievements, and outlook for the upcoming year. With a strong foothold in the realm of precision medicine and an array of impressive partnerships with pharmaceutical giants and biotech companies, Tempus is poised for continued success and growth in the foreseeable future.